Remove Clinical Development Remove Clinical Trials Remove Containment Remove Drugs
article thumbnail

Why Proactive AME Studies are Critical to Accelerating Your Approval Journey

Worldwide Clinical Trials

During clinical development, new chemical entities (NCEs) require an absorption, metabolism, and excretion (AME) study. Regardless of the formulation, the entire dose must be administered to each subject, and the dosing containers must be checked for residual radioactivity.

article thumbnail

This week in drug discovery (17-21 July)  

Drug Discovery World

The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant trial results for drugs for head and neck cancer and Alzheimer’s disease.

Drugs 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

Pfizer

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

article thumbnail

Multiple Dynamic Endpoints and the Role of Endpoint Adjudication Committees in Clinical Trials

Advarra

Sometimes, it can be as simple to determine as comparing drug A to placebo and measuring the physiological result with an approved assay. In most cases, the results you are really looking for and trying to prove in a trial can be complex. How do you know your experimental therapy is working?

article thumbnail

Hydrocortisone by Antares Pharma for Adrenal Insufficiency: Likelihood of Approval

Pharmaceutical Technology

Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is a combination of drug and device.

article thumbnail

ASP-2138 by Xencor for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Pharmaceutical Technology

ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Antibody 100
article thumbnail

ASP-2138 by Xencor for Gastric Cancer: Likelihood of Approval

Pharmaceutical Technology

ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. The drug candidate is being developed based on XmAb technology.

Antibody 100